Calcium polycarbophil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Calcium polycarbophil is a bulk forming laxative used to treat constipation.

Brand Names
Fiber Tab, Fibercon
Generic Name
Calcium polycarbophil
DrugBank Accession Number
DB14684
Background

Calcium polycarbophil is a stool stabilizer. Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea.

Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.

Type
Small Molecule
Groups
Approved
Synonyms
  • Calcium polycarbophil
  • Polycarbophil calcium
  • Polycarbophil, calcium

Pharmacology

Indication

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofConstipation••• ••••••••••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Mechanism of action

It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.

Absorption

Calcium polycarbophil is not absorbed from the intestine.

Volume of distribution

Calcium polycarbophil is not absorbed from the intestine.

Protein binding

Calcium polycarbophil is not absorbed from the intestine.

Metabolism

Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.

Route of elimination

Excreted in feces.

Half-life

Calcium polycarbophil is not absorbed from the intestine.

Clearance

Calcium polycarbophil is not absorbed from the intestine.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium polycarbophil.
AcetazolamideThe risk or severity of dehydration can be increased when Acetazolamide is combined with Calcium polycarbophil.
AcetyldigitoxinCalcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
AclidiniumThe therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aclidinium.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil.
Food Interactions
  • Take with a full glass of water.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
CalciumsaltSY7Q814VUP7440-70-2OYPRJOBELJOOCE-UHFFFAOYSA-N
PolycarbophilsaltW25LM17A4W9003-97-8Not applicable
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Best ChoiceTablet, film coated625 mg/1OralBest Choice (Valu Merchandisers Company)2019-04-16Not applicableUS flag
Calcium PolycarbophilTablet, film coated625 mg/1OralShandong Xinhua Pharmaceutical Co., Ltd.2023-04-12Not applicableUS flag
Calcium PolycarbophilTablet, film coated625 mg/1OralCVS Pharmacy, Inc2021-05-17Not applicableUS flag
Calcium PolycarbophilTablet, film coated625 mg/1OralCardinal Health2020-11-18Not applicableUS flag
Calcium Polycarbophil 625 mgTablet625 mg/1OralREMEDYREPACK INC.2016-10-102018-09-05US flag

Categories

ATC Codes
A06AC08 — Polycarbophil calcium
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8F049NKY49
CAS number
126040-58-2

References

General References
  1. Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [Article]
  2. Monograph [Link]
  3. webmd [Link]
Wikipedia
Polycarbophil_calcium

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral625 mg
TabletOral500 mg/1
Tablet, film coatedOral625 mg/1
TabletOral625 mg/1
CapsuleOral625 mg/1
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 06, 2018 02:00 / Updated at April 19, 2024 20:55